Clinical trial readout dates for Kyowa Kirin Co. Ltd., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is March 2027.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 2 KHK4951 Neovascular Age-Related Macular Degeneration (nAMD) · NCT06116890 | June 2026 Primary data collected |
| Phase 2 ziftomenib Acute Myeloid Leukemia (AML) · NCT07623616 | March 2027 Recruiting |
| Phase 1/2 KK2430 Hematologic Neoplasms · NCT07629726 | April 2027 Recruiting |
| Phase 2 ME-401 Indolent B-cell Non-Hodgkin's Lymphoma · NCT04533581 | May 2028 Ongoing |
| Phase 3 KK8398 Achondroplasia · NCT06926491 | May 2029 Ongoing |
| Phase 1/2 KK8123 X-linked Hypophosphatemia · NCT06525636 | June 2030 Recruiting |